Some stocks are expensive but work out well anyway due to exciting earnings growth. Other times the best way to make money is to simply buy shares which are temporarily undervalued due to unimpressive current results.
Israeli-based Teva Pharmaceutical (NASDAQ:TEVA) falls into the second category. Profits from continuing operations have been flattish over the past half-decade. EPS weighed in at $4.98 in 2011 and are expected to finish this year at around $5.16.
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association
Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2026 citybuzz
